Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.53 |
| ▸ | GPR52 | Q9Y2T5 | 3/20 | 0.45 |
| ▸ | BPGM | P07738 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 5/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24272024 | 0.89 | BPGM (0.50) | MRGPRX4GPR52BPGMPPARD | |
| SCHEMBL24272260 | 0.85 | BPGM (0.43) | MRGPRX4GPR52BPGMPPARD | |
| SCHEMBL24272267 | 0.83 | BPGM (0.51) | BPGMPPARDGABRA5 | |
| SCHEMBL24271765 | 0.82 | MRGPRX4 (0.53) | MRGPRX4GPR52BPGMPPARDSCN9A | |
| SCHEMBL24271780 | 0.81 | GPR52 (0.44) | GPR52BPGM | |
| SCHEMBL24271932 | 0.80 | BPGM (0.63) | GPR52BPGMPPARD | |
| SCHEMBL24271784 | 0.78 | ALDH1A1 (0.42) | GPR52BPGMPPARD | |
| SCHEMBL24271783 | 0.76 | BPGM (0.45) | GPR52BPGMPPARD | |
| SCHEMBL24271778 | 0.76 | BPGM (0.42) | GPR52BPGMPPARD | |
| SCHEMBL24271774 | 0.75 | BPGM (0.41) | GPR52BPGMPPARDGABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348450-A1 | CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | GENZYME CORPORATION | 2023-11-02 | — | — | US | disclosed |
| US-20230348450-A1 | CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | GENZYME CORPORATION | 2023-11-02 | — | — | US | disclosed |
| WO-2022056447-A1 | CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | GENZYME CORPORATION (US) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348450-A1 | CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | BPGM, PGAM1, PGM2 | MRGPRX4 2649/4885GPR52 2667/4885BPGM 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.